A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review

Table 1

A summary of all case reports describing immunotherapy for lung sarcomatoid carcinomas.

	Age/sex	Pathology	PD-L1 TPS (%)	Tx line	Treatment	Response	Duration of ICI treatment	Ref
1	66/M	Pleomorphic	≧95	2nd	Nivolumab	PD	6 cycles/discontinue	[9]
2	59/F	Pleomorphic	80-90	3rd	Nivolumab	PR	19 cycles/ongoing	[9]
3	83/M	Pleomorphic	60-70	4th	Nivolumab	PR	10 cycles/ongoing	[9]
4	55/M	Pleomorphic	90	2nd	Nivolumab	PR	9 cycles/discontinue	[10]
5	62/M	Pleomorphic	70	2nd	Nivolumab	PR	12 cycles/ongoing	[11]
6	67/M	Pleomorphic	≧50	7th	Nivolumab	PR	8 cycles/ongoing	[12]
7	74/M	Pleomorphic	≧50	3rd	Nivolumab	PR	28 months/ongoing	[13]
8	75/M	Pleomorphic	90	3rd	Nivolumab	CR	3 cycles/ongoing	[14]
9	82/M	Pleomorphic	75	1st	Pembrolizumab	PR	3 cycles/discontinue	[15]
10	51/M	Pleomorphic	≧50	1st	Pembrolizumab	PR	3 cycles/ongoing	[16]
11	57/M	Sarcomatoid	80-90	1st (post operation recurrence)	Nivolumab	CR	3 months/ongoing	[17]
12	60/M	Sarcomatoid	100	1st (post operation recurrence)	Nivolumab	PR	8 months/ongoing	[17]
Present	69/F	Giant cell	75	1st	Pembrolizumab	CR	4 cycles/discontinue	—